OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Grignani on the Future of Treatments for Sarcoma

June 8th 2017

Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the future of treatments for patients with soft tissue sarcoma.

Dr. Zulueta on the Application of the LuCED Test for Lung Cancer

June 6th 2017

Javier Zulueta, MD, head of the Pneumology Department, co-director, Lung Cancer Area, Clinica Universidad de Navarra, discusses an additional application of the LuCED test, a non-invasive tool used to detect early stage lung cancer.

Dr. Loeb on Tests for the Management of Prostate Cancer

June 6th 2017

Stacy Loeb, MD, assistant professor of Urology and Population Health at New York University, discusses test options to determine the management of patients newly diagnosed with prostate cancer.

Dr. Houber on the De-Escalation of Treatments for Breast Cancer

June 6th 2017

Jens Huober, MD, professor of gynecologic oncology, Ulm University Hospital, discusses the de-escalation of treatments for patients with breast cancer.

Dr. Badani on the Future of Robotic Surgery for Kidney Cancer

June 6th 2017

Ketan K. Badani, MD, professor of Urology at Mount Sinai Hospital, discusses the future of robotic surgery for patients with kidney cancer.

The Design Behind the Development of a Novel-Risk Prediction Model in Lung Cancer Screening

June 6th 2017

Joshua Roth, PhD, assistant member, Fred Hutchinson Cancer Research Center, discusses the design of a novel risk-prediction algorithm in the context of screening patients for lung cancer.

Dr. Kaouk on the Results of a Study of Robotic Surgery for RCC

June 6th 2017

Jihad Kaouk, MD, urologist, Cleveland Clinic, discusses the results of a study of robot-assisted partial nephrectomy for selected renal mass using an off-clamp approach compared to an on-clamp approach for patients with renal cell carcinoma (RCC).

Dr. Hayes on the Future of Biomarkers for Breast Cancer

June 6th 2017

Daniel F. Hayes, MD, professor at the University of Michigan Comprehensive Cancer Center, discusses the future of biomarkers for patients with breast cancer.

Dr. Feldman on the Significance of Active Surveillance in Prostate Cancer

June 6th 2017

Adam Scott Feldman, MD, MPH, urologist at Massachusetts General Hospital, assistant professor of Surgery, Harvard Medical School, discusses the significance of active surveillance for patients with prostate cancer.

Dr. Rugo on the Significance of the MONARCH I Trial for Breast Cancer

June 2nd 2017

Hope S. Rugo, MD, clinical professor, Department of Medicine, director, Breast Oncology Clinical Trials Program, of UCSF Helen Diller Family Comprehensive Cancer Center, discusses the significance of the MONARCH I study in hormone receptor-positive, HER2-negative breast cancer.

Dr. Stephenson on 2 Years Following the Management of Localized Prostate Cancer

June 2nd 2017

Andrew J. Stephenson, MD, director for the Center of Urologic Oncology at the Cleveland Clinic, discusses the significance of a study investigating urinary, bowel, and sexual function at 2 years following the management of localized prostate cancer.

Dr. Papadimitrakopoulou on Treatment Options for EGFR-Mutant NSCLC

June 2nd 2017

Vassiliki A. Papadimitrakopoulou, MD, professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with EGFR-mutant non-small cell lung cancer (NSCLC).

Dr. Abida on the Frequency of Mutations in Prostate Cancer

June 2nd 2017

Wassim Abida, MD, PhD, medical oncologist, Developmental Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the frequency of mutations for patients with prostate cancer.

Dr. Oh on AR-Targeted Therapy and Chemotherapy for CRPC

June 2nd 2017

William K. Oh, MD, chief, Division of Hematology and Medical Oncology, professor of Medicine and Urology, Mount Sinai School of Medicine, discusses AR-targeted therapy and chemotherapy for poor prognostic patients with castration-resistant prostate cancer.

Dr. Heymach on the Significance of Nivolumab for Lung Cancer

June 2nd 2017

John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the significance of nivolumab (Opdivo) for patients with lung cancer.

Dr. Barber on Neoadjuvant Chemotherapy in Ovarian Cancer

June 2nd 2017

Emma Barber, MD, UNC Department of Obstetrics and Gynecology, UNC School of Medicine, UNC Lineberger Comprehensive Cancer Center, discusses neoadjuvant chemotherapy lowering readmission rates for patients with ovarian cancer.

Dr. Hurvitz on Treatment Options for HER2-Positive Breast Cancer

June 2nd 2017

Sara Hurvitz, MD, Associate Professor of Medicine at UCLA, discusses treatment options for patients with HER2-positive breast cancer.

Dr. Wingo on Gynecologic Oncology Guidelines

June 2nd 2017

Shana Wingo, MD, gynecologic oncologist, Arizona Oncology, discusses gynecologic oncology guidelines.

Dr. Piccart on Personalized Care for Breast Cancer

May 31st 2017

Martine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses personalized care for patients with breast cancer.

Dr. Hayes Discusses Anti-Estrogen Therapy Beyond 5 Years in Breast Cancer

May 31st 2017

Daniel F. Hayes, MD, professor of University of Michigan Comprehensive Cancer Center, discusses anti-estrogen therapy beyond 5 years in breast cancer.